Chijioke Nze

Assistant professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

More than half of patients with relapsed/refractory (r/r) large B‐cell lymphoma (LBCL) experience progression after chimeric antigen receptor (CAR) T‐cell therapy, and subsequent treatment options remain limited with poor outcomes. Despite the need for effective therapies in this setting, post‐CAR T clinical trial enrolment is low. We conducted a single‐centre study of patients with r/r LBCL who progressed after CAR T‐cell therapy between January 2018 and September 2023 to describe the practice patterns and identify factors associated with clinical trial participation. Patient, disease and clinical characteristics were analysed across screening, enrolment and treatment phases. Among 166 patients who progressed after CAR T‐cell therapy, 39% were screened, 23% enrolled and 22% ultimately received trial treatment. High‐risk clinical features, including eastern cooperative oncology group (ECOG) performance status ≥2, stage IV disease, high‐risk International Prognostic Index, incomplete response to CAR T‐cell therapy and severe cytokine release syndrome, were associated with non‐participation. Using the eligibility criteria of pivotal trials that led to FDA approval of novel agents, only 14%–36% of patients who had relapsed disease after CAR T‐cell therapy were eligible for these trials. The study highlights the unmet need to develop trials that accommodate high‐risk populations to reduce barriers to trial participation following CAR T‐cell therapy failure.

Year:

2026

Hematologic malignancies exhibit disparities in risk and outcomes across populations. A systematic review to identify prospective studies addressing disparities among patients with hematologic malignancies with an intervention or analysis at any level in the “Cells-to-Society” model identified few studies and demonstrated literature gaps, which experts have supplemented with relevant citations. This review presents current research on diagnosis, treatment, and survival disparities and explores the roles of biology, cancer centers, community outreach, patient advocacy, and policies. Emphasis is placed on multilevel collaborative approaches to promote equity in healthcare delivery and improve survival. Significance: This review underscores our shared responsibility to champion multidimensional strategies rooted in basic and translational science, community involvement, and societal responsiveness for a meaningful impact. Unifying themes include the need to enhance collaborative infrastructure to engage laboratory researchers, epidemiologists, data scientists, clinicians, patients, community leaders, and policymakers; patient-level support services; outreach, education, and navigation for patients at the community level; recruitment and retention of underrepresented groups in the healthcare and research workforce; and funding for these efforts.

Year:

2025

Anaplastic lymphoma kinase‐positive large B‐cell lymphoma (ALK+ LBCL) is a rare, aggressive subtype of diffuse large B‐cell lymphoma with poor outcomes using standard chemotherapy. In this multi‐institutional retrospective study, we analyzed 39 cases of ALK+ LBCL identified at six US academic centers from 2002 to 2024, with treatment including conventional cytotoxic regimens in frontline and biologically informed and nonchemotherapy‐based strategies in the relapsed setting. Ninety‐two percent of patients received frontline anthracycline‐based chemotherapy; 43% received intensified regimens, and 15% underwent upfront autologous stem cell transplantation (ASCT). Despite these approaches, outcomes remained poor. At a median follow‐up of 5.4 years, median event‐free survival (EFS) was 0.6 years (95% CI, 0.4–0.9), and median overall survival (OS) was 1.5 years (95% CI, 1.3–NR). One‐ and five‐year EFS rates were 28% and 17%, while corresponding OS rates were 72% and 42%, respectively. Advanced stage and high IPI scores were associated with inferior outcomes. Twelve patients received ALK inhibitors, with alectinib showing more durable responses than crizotinib. Lenalidomide and immune checkpoint inhibitors also demonstrated activity, including durable complete responses. Five patients underwent allogeneic stem cell transplantation, with three achieving sustained remission. In conclusion, our findings highlight the limited benefit of chemotherapy, even when intensified or followed by ASCT, and support the integration of biologically targeted therapies, which may have contributed to improved OS in our cohort compared to historical outcomes. Prospective, collaborative studies are needed to better understand disease biology and define optimal use of modern therapies in this rare lymphoma.

Year:

2025

While the incidence and survival associated with lymphoma have improved in recent years, outcome disparities related to sociodemographic factors such as age, sex, race, ethnicity, socioeconomic status (SES), and other social determinants of health (SDOH) remain prevalent in the modern era. Clinical trials are crucial for further improving outcomes, yet not all sociodemographic groups are equally represented in contemporary lymphoma trials. We conducted a systematic review of the literature evaluating the impact of SDOH on enrollment into clinical trials in the United States and identified 21 relevant studies. We confirmed that Black and Hispanic individuals are underrepresented in lymphoma clinical trials, due largely to the geographic distribution of clinical trial sites and exacerbated by globalization of cancer trials. Women may also be less appropriately represented than men, although this association is less robust and consistent. Adolescents and young adults with lymphoma who are older, treated at adult cancer centers, or managed by adult hematologists/oncologists are all less likely to be part of trials. Older adults are also excluded from most lymphoma clinical trials. There is a dearth of data on how other SDOHs including education, employment, and household income contribute to differences in clinical trial enrollment. Further research is required to explore the intersection of demographics, SES, insurance status, and enrollment into lymphoma clinical trials.

Year:

2025

New lymphoma treatments, including chimeric antigen receptor T cells, bispecific antibodies, and immune checkpoint inhibitors, have significantly improved patient outcomes. Despite these therapeutic advances, only 2% to 3% of adult patients with cancer participate in clinical trials. This participation is even lower among certain groups, including ethnic and racial minorities, individuals with low socioeconomic status, rural residents, older adults, and young adults. Underrepresentation of these groups in clinical trials limits the generalizability of trial results and is detrimental to those populations that do not receive equal access to novel therapies. Although racial and ethnic minorities constitute >40% of the US population, they make up only ∼15% of clinical trial participants. The US Food and Drug Administration now requires sponsors seeking regulatory approval for therapies via registrational clinical trials to submit a plan to ensure diversity among trial participants. This article addresses strategies for enhancing enrollment of underrepresented minorities in lymphoma clinical trials.

Year:

2025

Hematologic malignancies exhibit disparities in risk and outcomes across populations. A systematic review to identify prospective studies addressing disparities among patients with hematologic malignancies with an intervention or analysis at any level in the “Cells-to-Society” model identified few studies and demonstrated literature gaps, which experts have supplemented with relevant citations. This review presents current research on diagnosis, treatment, and survival disparities and explores the roles of biology, cancer centers, community outreach, patient advocacy, and policies. Emphasis is placed on multilevel collaborative approaches to promote equity in healthcare delivery and improve survival. Significance: This review underscores our shared responsibility to champion multidimensional strategies rooted in basic and translational science, community involvement, and societal responsiveness for a meaningful impact. Unifying themes include the need to enhance collaborative infrastructure to engage laboratory researchers, epidemiologists, data scientists, clinicians, patients, community leaders, and policymakers; patient-level support services; outreach, education, and navigation for patients at the community level; recruitment and retention of underrepresented groups in the healthcare and research workforce; and funding for these efforts.

Year:

2025

Year:

2024

Prior studies have demonstrated that certain populations including older patients, racial/ethnic minority groups, and women are underrepresented in clinical trials. We performed a retrospective analysis of patients with non-Hodgkin lymphoma (NHL) seen at MD Anderson Cancer Center (MDACC) to investigate the association between trial participation, race/ethnicity, travel distance, and neighborhood socioeconomic status (nSES). Using patient addresses, we ascertained nSES variables on educational attainment, income, poverty, racial composition, and housing at the census tract (CT) level. We also performed geospatial analysis to determine the geographic distribution of clinical trial participants and distance from patient residence to MDACC. We examined 3146 consecutive adult patients with NHL seen between January 2017 and December 2020. The study cohort was predominantly male and non-Hispanic White (NHW). The most common insurance types were private insurance and Medicare; only 1.1% of patients had Medicaid. There was a high overall participation rate of 30.5%, with 20.9% enrolled in therapeutic trials. In univariate analyses, lower participation rates were associated with lower nSES including higher poverty rates and living in crowded households. Racial composition of CT was not associated with differences in trial participation. In multivariable analysis, trial participation varied significantly by histology, and participation declined nonlinearly with age in the overall, follicular lymphoma, and diffuse large B-cell lymphoma (DLBCL) models. In the DLBCL subset, Hispanic patients had lower odds of participation than White patients (odds ratio, 0.36; 95% confidence interval, 0.21-0.62; P = .001). In our large academic cohort, race, sex, insurance type, and nSES were not associated with trial participation, whereas age and diagnosis were.

Year:

2024

Year:

2023

Collaborators (12)

Pavlos Msaouel

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

sairah ahmed

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Wendy Cozen

Professor

University of California, Irvine

UNITED STATES
View details

Bettzy Stephen

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Michelle Hildebrandt

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Rulla Tamimi

Professor

Weill Cornell Medicine

UNITED STATES
View details

Paolo Strati

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Rock Bum Kim

Seoul National University Hospital

SOUTH KOREA
View details

Swaminathan P. Iyer

Professor of Medicine

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Akiva Diamond

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Jeremy Ramdial

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ari M. Melnick

Director

Josep Carreras Leukaemia Research Institute

SPAIN
View details